Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome

Conclusion: Adult patients and caregivers of pediatric patients indicated an overall preference for ravulizumab than eculizumab for the treatment of aHUS, driven primarily by infusion frequency. This study contributes to the emerging real-world evidence on the treatment impact and preference in patients with aHUS.PMID:37515502 | DOI:10.57264/cer-2023-0036

Source: Journal of Comparative Effectiveness Research - July 29, 2023 Category: General Medicine Authors: Teri J Mauch Michael R Chladek Spero Cataland Shruti Chaturvedi Bradley P Dixon Katherine Garlo Christoph Gasteyger Anuja Java Jorge Leguizamo Lucy Lloyd-Price Tan P Pham Tara Symonds Ioannis Tomazos Yan Wang Source Type: research